The ATMP classification is a strong validation of our innovative approach and pTTL's potential as a breakthrough cancer therapy. It provides regulatory clarity and invaluable guidance from the EMA, enabling us to advance development efficiently and effectively. We are now well-positioned to continue our work towards delivering transformative treatments to cancer patients.

Partnering with NorthX Biologics is an important step in preparing our therapy for future trials beyond the current Phase 1 study. Establishing a reliable and cost-effective manufacturing process is key to our clinical and commercial goals. We’re excited for our team to work closely with NorthX’s experts, combining our strengths to develop a scalable solution that will allow us to treat a larger patient population as we advance.

With the newly granted patent in China, we are not only strengthening our international position in biotechnology but also expanding the applications of our EpiTCer® technology. While our primary focus remains on developing cancer treatments, this patent also opens new avenues for the treatment and diagnosis of MS. It demonstrates our ability to successfully expand our research areas to include other serious health conditions, contributing to our capacity to offer even more effective solutions for combating both cancer and autoimmune diseases.

We are very grateful for Eurostars' backing, which not only recognises the scientific potential of our company but also reinforces our role as an innovator in analysis methods for next-generation cell therapies. The funding enables further research that is essential for advancing our cell therapy product to later clinical phases.

The new patent marks a milestone that not only strengthens our IP portfolio but also reflects the great potential of our EpiTCer® platform. While our primary focus remains on cancer treatment, this patent also signifies an exciting expansion of our research into other vital areas, including MS, where we see considerable potential for our EpiTCer® technology. This development allows us to build further on our previous successes in identifying specific molecular markers for MS diagnosis and take an important step forward in our research and development of innovative treatments for autoimmune diseases.

These capital injections are a clear endorsement of the innovative spirit and dedicated efforts that define Neogap's work. The EU funding confirms our ambition to be a driving force in the field of cancer therapy. With these resources, we can continue our development work as planned, bringing us closer to our long-term objective – to improve treatment options and increase the survival chances for cancer patients.

We are very pleased and proud to see that Neogap was selected as one of the most promising Swedish companies by the Catalyst committee. We look forward to collaborating with Business Sweden, exploring strategic international partnerships, and finding potential investors in our innovative cell therapy pTTL.

We are delighted to acquire the remaining shares in TCER Oncology and extend a warm welcome to Rolf Kiessling and Stina Wickström as valued shareholders in Neogap. This acquisition marks a momentous milestone, fortifying our standing in personalised immunotherapy. It allows us to expand our patent portfolio and pipeline of potential drug candidates while further developing our innovations in the field. We look forward to continuing to drive progress and deliver groundbreaking scientific breakthroughs in cancer treatment.

We are pleased that Neogap has been granted this patent in Europe. Our continuous evaluation of intellectual property rights ensures the protection of our unique cancer therapies. Our focus is to develop our treatments for personalised immunotherapy, to increase survival rates and improve the quality of life for cancer patients.

We are delighted, not only because the acquired knowledge can be harnessed to develop personalised therapies for the lifelong suffering associated with multiple sclerosis, but also because we have obtained additional evidence that our technology platform holds substantial relevance across multiple disease fields, encompassing autoimmune disorders and other immune-related conditions. We are committed to advancing pioneering applications for EpiTCer® and making significant contributions to developing novel therapies for treating severe illnesses.

Enrolling the first patient in our Phase I/II clinical trial is a momentous occasion for Neogap. We are both humbled and excited by this achievement. It signifies our dedication to advancing cancer treatment by enhancing the immune system's tumour-specific responses, ultimately increasing overall survival. I am immensely proud of our team's hard work and determination. This important transition propels Neogap into a clinical-stage company, bringing us closer to realising our vision of delivering effective treatment for solid cancers.

We are delighted to welcome Alejandro Fernandez Woodbridge to our team. With over two decades of experience in bioinformatics and software development, his distinguished background will be invaluable for further development of PIOR® in the field of cell therapy and diagnostics.

We are thrilled to contribute to and be a part of Cellerys upcoming Phase II study, where EpiTCer® will be a key aspect in monitoring autoreactive T cells. The collaboration with Cellerys opens up opportunities for Neogap to use our technology platform in several disease fields, including autoimmune diseases and other immune-related conditions. Our goal is to continue to develop innovative applications for EpiTCer® and contribute to the development of new therapies for the treatment of severe diseases.

We are thrilled to welcome Dr. Hanjing Xie as our new Chief Medical Officer. With extensive experience in research, clinical development, and patient care, Dr. Xie brings a wealth of expertise to Neogap. Her diverse background in the pharmaceutical industry and academia, along with specialised training in clinical oncology, and hematology, make her highly qualified to lead our cell therapy trial.

Our technology PIOR® is a safe and regulated system for bioinformatic analysis of sequencing data that is also user-friendly. This provides the advantage of securely handling patient data while having the potential for multiple future applications in diagnostics and precision medicine. The collaboration with Simsen is an important step in expanding the PIOR® technology towards future commercialization and out-licensing of PIOR®, which is very exciting for us.

The approval and the prompt initiation of the clinical trial represent significant milestones for Neogap. We have demonstrated that we can take an advanced cell therapy product from preclinical to clinical development. I am very proud of our skilled and committed team who, together with experienced partners, have brought us to this important point. As a result, we are now taking a big step towards our goal of curing cancer patients who would otherwise not survive.

We are very pleased that we have got a Notice of Allowance in Europe for this patent application which adds increased value to our immune-oncology pipeline and strengthens NEOGAP's patent portfolio.

We would like to extend a warm welcome to Anna Kälvemark and Steve Glavas to Neogap's board. They are an ideal complement to Neogap's board at a stage when we are about to enter the clinical phase.

By identifying a patient's personal autoantigen profile, treatment can be adapted for that particular individual. T cells drive most autoimmune diseases, and if we can find a way to silence them in a disease such as MS, it can pave the way for a more precise way to treat other autoimmune diseases as well.

The results demonstrate the potential of our EpiTCer® technology and further strengthen our belief that the choice of neoantigens, and how to administer them, are critical parameters for the production of potent, tumour-targeted T cells and the foundation for successful immunotherapeutic treatment.